-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria sees oral GLP-1 pill market reaching $17 billion-$60 billion by mid-2030s

PUBT·04/21/2026 13:10:24
Listen to the news
Lexaria sees oral GLP-1 pill market reaching $17 billion-$60 billion by mid-2030s
  • Lexaria projected oral GLP-1 weight-loss pills could generate USD 17 billion to USD 60 billion in annual sales by mid-2030s, based on industry forecasts for total GLP-1 market size.
  • Novo Nordisk disclosed more than 600,000 prescriptions for Wegovy pill were written in first two months following January 2026 US launch.
  • GlobalData forecast 51% of Wegovy revenue growth from 2026-2031 to come from pill format, with franchise expected to reach USD 15.9 billion in annual revenue by 2030.
  • Novo Nordisk executive estimate cited oral GLP-1 drugs could reach 33% of broader GLP-1 market within a few years of launch.
  • Lexaria positioned DehydraTECH as an oral-delivery enhancer for semaglutide, tirzepatide, liraglutide, with 2026 R&D plans to assess next-generation GLP-1 candidates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604210910ACCESSWRNAPR_____1159254) on April 21, 2026, and is solely responsible for the information contained therein.